Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C

Research output: Contribution to journalArticle

Abstract

Many of the major advances in treating patients for chronic hepatitis C have been made based on the results of randomized, double-blind, controlled clinical trials. However, given the large number of hepatitis C medications in development, physicians need to understand the unique elements and types of clinical trials in order to make accurate comparisons of differing drug efficacy claims. Clinicians also need to be aware of the various factors that can influence the outcomes and interpretations of these trials, irrespective of the intervention under study. For example, similar trials conducted in the United States and Europe may have different outcomes simply because the study populations differ. Thus, both trial design and patient population are important considerations in the design and analysis of clinical trials for patients with chronic hepatitis C.

Original languageEnglish
Pages (from-to)6-14
Number of pages9
JournalJournal of Viral Hepatitis
Volume13
Issue numberSUPPL. 1
DOIs
StatePublished - May 1 2006

Fingerprint

Chronic Hepatitis C
Clinical Trials
Controlled Clinical Trials
Hepatitis C
Population
Therapeutics
Physicians
Pharmaceutical Preparations

Keywords

  • Clinical trial design
  • Experimental therapies
  • Hepatitis C
  • Interferon
  • Ribavirin

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C. / O'Brien, Christopher B.

In: Journal of Viral Hepatitis, Vol. 13, No. SUPPL. 1, 01.05.2006, p. 6-14.

Research output: Contribution to journalArticle

@article{1303fb6e375d4b5cbda56b01bd74d54b,
title = "Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C",
abstract = "Many of the major advances in treating patients for chronic hepatitis C have been made based on the results of randomized, double-blind, controlled clinical trials. However, given the large number of hepatitis C medications in development, physicians need to understand the unique elements and types of clinical trials in order to make accurate comparisons of differing drug efficacy claims. Clinicians also need to be aware of the various factors that can influence the outcomes and interpretations of these trials, irrespective of the intervention under study. For example, similar trials conducted in the United States and Europe may have different outcomes simply because the study populations differ. Thus, both trial design and patient population are important considerations in the design and analysis of clinical trials for patients with chronic hepatitis C.",
keywords = "Clinical trial design, Experimental therapies, Hepatitis C, Interferon, Ribavirin",
author = "O'Brien, {Christopher B}",
year = "2006",
month = "5",
day = "1",
doi = "10.1111/j.1365-2893.2006.00757.x",
language = "English",
volume = "13",
pages = "6--14",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C

AU - O'Brien, Christopher B

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Many of the major advances in treating patients for chronic hepatitis C have been made based on the results of randomized, double-blind, controlled clinical trials. However, given the large number of hepatitis C medications in development, physicians need to understand the unique elements and types of clinical trials in order to make accurate comparisons of differing drug efficacy claims. Clinicians also need to be aware of the various factors that can influence the outcomes and interpretations of these trials, irrespective of the intervention under study. For example, similar trials conducted in the United States and Europe may have different outcomes simply because the study populations differ. Thus, both trial design and patient population are important considerations in the design and analysis of clinical trials for patients with chronic hepatitis C.

AB - Many of the major advances in treating patients for chronic hepatitis C have been made based on the results of randomized, double-blind, controlled clinical trials. However, given the large number of hepatitis C medications in development, physicians need to understand the unique elements and types of clinical trials in order to make accurate comparisons of differing drug efficacy claims. Clinicians also need to be aware of the various factors that can influence the outcomes and interpretations of these trials, irrespective of the intervention under study. For example, similar trials conducted in the United States and Europe may have different outcomes simply because the study populations differ. Thus, both trial design and patient population are important considerations in the design and analysis of clinical trials for patients with chronic hepatitis C.

KW - Clinical trial design

KW - Experimental therapies

KW - Hepatitis C

KW - Interferon

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=33645805478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645805478&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2006.00757.x

DO - 10.1111/j.1365-2893.2006.00757.x

M3 - Article

C2 - 16630042

AN - SCOPUS:33645805478

VL - 13

SP - 6

EP - 14

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - SUPPL. 1

ER -